Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Monday, March 26, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation

COPENHAGEN,

Denmark, March 26, 2018 /PRNewswire/ -- Genmab A/S (CPH: GEN, OTC:GMXAY), focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer, today announced that their
March 22
nd presentation from Genmab's Senior Vice President, IR & Communications, Rachel Curtis Gravesen, is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.

LINK:    https://tinyurl.com/dbvic03postpr

Genmab A/S' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.

About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEXŪ (daratumumab) for the treatment of certain multiple myeloma indications, and ArzerraŪ (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBodyŪ platform for generation of bispecific antibodies, and the HexaBodyŪ platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/genmab-as-webcast-presentation-now-available-for-on-demand-viewing-dbvic---deutsche-bank-adr-virtual-investor-conference-300619201.html

SOURCE Genmab A/S



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store